Croda International PLC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croda International PLC


Website: www.croda.com/healthcare

E-mail: hc-europe@croda.com

Croda International Plc is a UK-based manufacturer and worldwide supplier of oleochemicals offering one of the widest ranges of chemical specialties, surfactants, and high-purity lipids available to the pharmaceutical industry with products manufactured at multiple sites throughout the world.

Croda manufactures excipients of superior quality and purity for the global pharmaceutical market. Croda developed and utilises a proprietary flash chromatographic process called Super Refining. This process physically removes impurities from pharmaceutical excipients without altering their fundamental structure in any way. This process allows the offering of a range of high purity excipients that can improve API and formulation stability.

Croda offers a complete range of products for topical dosage forms as well as high-purity multicompendial solvents, solubilisers and surfactants suitable for parenteral, oral and ophthalmic formulations. Featured products include Super Refined ingredients: Oils, Oleic Acid, Oleyl Alcohol, Isopropyl Myristate, PEGs, Polysorbates, Dimethyl Isosorbide, Medical Grade Lanolins, Poloxamers and Omega 3 Fatty Acid Concentrates.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here